[{"id":1,"annotations":[{"id":1,"completed_by":1,"result":[{"value":{"start":0,"end":30,"text":"Malignant pleural mesothelioma","labels":["CONDITION"]},"id":"YSfMmuBBed","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":32,"end":35,"text":"MPM","labels":["CONDITION"]},"id":"z-T27MjONY","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":42,"end":49,"text":"cancer ","labels":["CONDITION"]},"id":"fgQqrf9ywq","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T17:18:04.738957Z","updated_at":"2025-12-25T17:18:04.738957Z","draft_created_at":"2025-12-25T17:16:53.012385Z","lead_time":117.281,"prediction":{},"result_count":3,"unique_id":"4b32310a-a7f6-43e3-837f-6e1925f00ab2","import_id":null,"last_action":null,"bulk_created":false,"task":1,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":4,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"1 day","result":[{"value":{"start":0,"end":30,"text":"Malignant pleural mesothelioma","labels":["CONDITION"]},"id":"YSfMmuBBed","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":32,"end":35,"text":"MPM","labels":["CONDITION"]},"id":"z-T27MjONY","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":152.512,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T17:30:57.487044Z","updated_at":"2025-12-25T17:37:31.616678Z","task":1,"annotation":1}],"predictions":[],"data":{"text":"Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options.essentially all patients usually progress and die subsequently to a first line therapyl."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T17:18:04.786957Z","allow_skip":true,"inner_id":1,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":2,"annotations":[{"id":2,"completed_by":1,"result":[{"value":{"start":0,"end":11,"text":"Durvalumab ","labels":["DRUG"]},"id":"7MgbLC6DNK","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":99,"end":130,"text":"metastatic urothelial carcinoma","labels":["CONDITION"]},"id":"CjwuOKitOn","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T17:19:06.385023Z","updated_at":"2025-12-25T17:19:06.385023Z","draft_created_at":"2025-12-25T17:18:19.608468Z","lead_time":58.462,"prediction":{},"result_count":2,"unique_id":"b2047dcd-9673-455e-b5ac-ac385f12f13a","import_id":null,"last_action":null,"bulk_created":false,"task":2,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":5,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"1 day","result":[{"value":{"start":0,"end":11,"text":"Durvalumab ","labels":["DRUG"]},"id":"7MgbLC6DNK","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":79,"end":130,"text":"locally advanced or metastatic urothelial carcinoma","labels":["CONDITION"]},"id":"ZCvcnHqmG1","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":62.107,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T17:38:43.410271Z","updated_at":"2025-12-25T17:38:56.103785Z","task":2,"annotation":2}],"predictions":[],"data":{"text":"Durvalumab has received FDA approval as second line treatment in patients with locally advanced or metastatic urothelial carcinoma."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T17:19:06.421019Z","allow_skip":true,"inner_id":2,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":3,"annotations":[{"id":3,"completed_by":1,"result":[{"value":{"start":38,"end":46,"text":"Phase II","labels":["STUDY_PHASE"]},"id":"5qe1r1RCAY","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":113,"end":124,"text":"Durvalumab ","labels":["DRUG"]},"id":"eAxNRWDT6f","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":26,"end":34,"text":"PD-L1 Ab","labels":["BIOMARKER"]},"id":"YONUQ-O-dr","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":127,"end":150,"text":"advanced pretreated MPM","labels":["CONDITION"]},"id":"ZKv4IFxION","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":90,"end":98,"text":"activity","labels":["ENDPOINT"]},"id":"njI3fgfJI8","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":103,"end":109,"text":"safety","labels":["ENDPOINT"]},"id":"PqcHyCvBuU","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:04:21.274968Z","updated_at":"2025-12-25T18:04:21.274968Z","draft_created_at":"2025-12-25T17:19:26.449045Z","lead_time":291.603,"prediction":{},"result_count":6,"unique_id":"8e8cc089-5292-4d37-a901-d2ac0b816220","import_id":null,"last_action":null,"bulk_created":false,"task":3,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Given these prospects for PD-L1 Ab, a Phase II study is proposed in order to evaluate the activity and safety of Durvalumab in advanced pretreated MPM."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T18:04:21.341387Z","allow_skip":true,"inner_id":3,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":4,"annotations":[{"id":4,"completed_by":1,"result":[{"value":{"start":32,"end":35,"text":"MPM","labels":["CONDITION"]},"id":"FxeKqKAvpJ","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":30,"text":"Malignant pleural mesothelioma","labels":["CONDITION"]},"id":"IMllSxk0sm","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:04:23.406854Z","updated_at":"2025-12-25T18:04:23.406854Z","draft_created_at":"2025-12-25T17:43:11.315933Z","lead_time":14.685,"prediction":{},"result_count":2,"unique_id":"09bc4cea-1a00-441a-b613-af7dd00c536e","import_id":null,"last_action":null,"bulk_created":false,"task":4,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T18:04:23.478006Z","allow_skip":true,"inner_id":4,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":5,"annotations":[{"id":5,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:34:40.052769Z","updated_at":"2025-12-25T18:34:40.052769Z","draft_created_at":null,"lead_time":1814.91,"prediction":{},"result_count":0,"unique_id":"075f3305-79db-4ad4-8e7c-be31f2a09353","import_id":null,"last_action":null,"bulk_created":false,"task":5,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Its incidence is growing fast worldwide and is associated with asbestos exposure, a well known cancerogenic factor driving the development of this cancer."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T18:34:40.117083Z","allow_skip":true,"inner_id":5,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":6,"annotations":[{"id":6,"completed_by":1,"result":[{"value":{"start":10,"end":14,"text":"MPM ","labels":["CONDITION"]},"id":"PqIZrmhFS0","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:35:36.726090Z","updated_at":"2025-12-25T18:35:36.726090Z","draft_created_at":"2025-12-25T18:34:52.147233Z","lead_time":53.98,"prediction":{},"result_count":1,"unique_id":"2b9639f9-16ac-4ab6-abf9-7e2edf3d4511","import_id":null,"last_action":null,"bulk_created":false,"task":6,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Generally MPM is diagnosed at an advanced inoperable stage and most frequently the only therapeutic approach is palliative chemotherapy."},"meta":{},"created_at":"2025-12-25T17:15:25.256786Z","updated_at":"2025-12-25T18:35:36.768014Z","allow_skip":true,"inner_id":6,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":7,"annotations":[{"id":7,"completed_by":1,"result":[{"value":{"start":76,"end":78,"text":"OS","labels":["ENDPOINT"]},"id":"NciOpkx8At","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":118,"end":121,"text":"PFS","labels":["ENDPOINT"]},"id":"w6lXhWb-oH","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":91,"end":116,"text":"progression free survival","labels":["ENDPOINT"]},"id":"RZRQ0tLLSv","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":58,"end":74,"text":"overall survival","labels":["ENDPOINT"]},"id":"RqxiuWdWss","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":28,"text":"Platinum-pemetrexed doublets","labels":["DRUG"]},"id":"_7gH_ZglNS","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:37:44.227186Z","updated_at":"2025-12-25T18:37:44.227186Z","draft_created_at":"2025-12-25T18:36:02.161416Z","lead_time":125.88,"prediction":{},"result_count":5,"unique_id":"dac488ed-30e6-43bb-abfe-85541ff68793","import_id":null,"last_action":null,"bulk_created":false,"task":7,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Platinum-pemetrexed doublets prolong significantly median overall survival (OS) and median progression free survival (PFS) with respect to platinum alone and are considered the only therapeutic option in a first line setting."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:37:44.282790Z","allow_skip":true,"inner_id":7,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":8,"annotations":[{"id":8,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:38:10.185143Z","updated_at":"2025-12-25T18:38:10.185143Z","draft_created_at":null,"lead_time":24.108,"prediction":{},"result_count":0,"unique_id":"1b6ade25-8606-4c5a-b27d-ccef0addbd74","import_id":null,"last_action":null,"bulk_created":false,"task":8,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Unfortunately, essentially all patients usually progress and die subsequently to a first line therapyl."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:38:10.222680Z","allow_skip":true,"inner_id":8,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":9,"annotations":[{"id":9,"completed_by":1,"result":[{"value":{"start":40,"end":65,"text":"advanced unresectable MPM","labels":["CONDITION"]},"id":"WmXlRvtYyZ","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":14,"end":65,"text":"Histological diagnosis of advanced unresectable MPM","labels":["PATIENT_CRITERIA"]},"id":"TiITp33FlI","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:39:53.250563Z","updated_at":"2025-12-25T18:39:53.250563Z","draft_created_at":"2025-12-25T18:38:29.640373Z","lead_time":100.499,"prediction":{},"result_count":2,"unique_id":"c9d0613a-5b94-414c-a5ea-4098c5483c85","import_id":null,"last_action":null,"bulk_created":false,"task":9,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":29,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"19 hours, 6 minutes","result":[{"value":{"start":40,"end":65,"text":"advanced unresectable MPM","labels":["CONDITION"]},"id":"WmXlRvtYyZ","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":65,"text":"Inclusion: 1. Histological diagnosis of advanced unresectable MPM","labels":["PATIENT_CRITERIA"]},"id":"tl_0j6QMVp","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":8.27,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T23:02:10.329593Z","updated_at":"2025-12-25T23:02:10.329593Z","task":9,"annotation":9}],"predictions":[],"data":{"text":"Inclusion: 1. Histological diagnosis of advanced unresectable MPM;"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:39:53.301376Z","allow_skip":true,"inner_id":9,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":10,"annotations":[{"id":10,"completed_by":1,"result":[{"value":{"start":3,"end":181,"text":"Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 5 unstained slides for central determination of PD-L1 expression","labels":["PATIENT_CRITERIA"]},"id":"wO0qSMSvWL","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":165,"end":181,"text":"PD-L1 expression","labels":["BIOMARKER"]},"id":"Qc-y4C9zKN","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:42:50.503669Z","updated_at":"2025-12-25T18:42:50.503669Z","draft_created_at":"2025-12-25T18:41:49.614440Z","lead_time":172.03,"prediction":{},"result_count":2,"unique_id":"53a79f56-51a0-46ff-b8f5-0def5ad67ae8","import_id":null,"last_action":null,"bulk_created":false,"task":10,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"2. Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (preferred) or at least 5 unstained slides for central determination of PD-L1 expression;"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:42:50.551803Z","allow_skip":true,"inner_id":10,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":11,"annotations":[{"id":11,"completed_by":1,"result":[{"value":{"start":0,"end":16,"text":"Primary endpoint","labels":["BIOMARKER"]},"id":"W0HXnMgdSk","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":18,"end":49,"text":"Proportion of survived patients","labels":["ENDPOINT"]},"id":"oLsPln_Tao","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:50:22.266911Z","updated_at":"2025-12-25T18:50:22.266911Z","draft_created_at":"2025-12-25T18:49:30.311325Z","lead_time":449.399,"prediction":{},"result_count":2,"unique_id":"f4521680-5b35-4634-b16e-1bfe7bd22b54","import_id":null,"last_action":null,"bulk_created":false,"task":11,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Proportion of survived patients at 16 weeks [Time Frame: 16 weeks]"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:50:22.335793Z","allow_skip":true,"inner_id":11,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":12,"annotations":[{"id":12,"completed_by":1,"result":[{"value":{"start":6,"end":16,"text":"Durvalumab","labels":["DRUG"]},"id":"p8Oivs8-hH","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T18:53:08.171057Z","updated_at":"2025-12-25T18:53:08.171057Z","draft_created_at":"2025-12-25T18:50:50.194968Z","lead_time":162.181,"prediction":{},"result_count":1,"unique_id":"845e6a49-c1ca-4184-8e26-6dfc4fdf8d8b","import_id":null,"last_action":null,"bulk_created":false,"task":12,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"DRUG: Durvalumab - Durvalumab in monotherapy as second line treatment"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T18:53:08.244438Z","allow_skip":true,"inner_id":12,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":13,"annotations":[{"id":13,"completed_by":1,"result":[{"value":{"start":267,"end":300,"text":"relapsed\/refractory Neuroblastoma","labels":["CONDITION"]},"id":"qs4_AUhO5S","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":114,"end":120,"text":"safety","labels":["ENDPOINT"]},"id":"iyjuVfTSbt","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":122,"end":142,"text":"preliminary efficacy","labels":["ENDPOINT"]},"id":"UzOgq8y-9d","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":144,"end":160,"text":"pharmacokinetics","labels":["ENDPOINT"]},"id":"9JEK70CVYm","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":232,"end":238,"text":"CNK-UT","labels":["DRUG"]},"id":"mg8uR3txEV","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":198,"end":230,"text":"chimeric natural killer receptor","labels":["DRUG"]},"id":"36GCDaOiN4","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T19:04:04.327256Z","updated_at":"2025-12-25T19:04:04.327256Z","draft_created_at":"2025-12-25T18:53:47.957443Z","lead_time":654.551,"prediction":{},"result_count":6,"unique_id":"89530333-cb69-452a-a180-352ab3394b4f","import_id":null,"last_action":null,"bulk_created":false,"task":13,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed\/refractory Neuroblastoma."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T19:04:04.391040Z","allow_skip":true,"inner_id":13,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":14,"annotations":[{"id":14,"completed_by":1,"result":[{"value":{"start":34,"end":41,"text":"phase I","labels":["STUDY_PHASE"]},"id":"bBNl5OUN81","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":104,"end":124,"text":"CNK-UT cells therapy","labels":["DRUG"]},"id":"a8omFDvXXk","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":238,"end":271,"text":"relapsed\/refractory Neuroblastoma","labels":["CONDITION"]},"id":"0PjD69AciT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":169,"end":186,"text":"pharmacokinetics ","labels":["ENDPOINT"]},"id":"i83IfUZlAN","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":94,"end":101,"text":"safety ","labels":["ENDPOINT"]},"id":"HzgsjnwvSN","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":144,"end":164,"text":"preliminary efficacy","labels":["ENDPOINT"]},"id":"zxJibsstgK","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T19:31:51.927232Z","updated_at":"2025-12-25T19:31:51.927232Z","draft_created_at":"2025-12-25T19:27:01.718007Z","lead_time":1665.669,"prediction":{},"result_count":6,"unique_id":"c805986c-5771-4a68-a627-adba53d8e810","import_id":null,"last_action":null,"bulk_created":false,"task":14,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This is a single arm, open-label, phase I, dose escalation\/dose expansion study to assess the safety of CNK-UT cells therapy, and to obtain the preliminary efficacy and pharmacokinetics result in participants who have been diagnosed with relapsed\/refractory Neuroblastoma."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T19:31:51.977356Z","allow_skip":true,"inner_id":14,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":15,"annotations":[{"id":15,"completed_by":1,"result":[{"value":{"start":14,"end":62,"text":"Aged 1-12 years with weight≥10kg, male or female","labels":["PATIENT_CRITERIA"]},"id":"AnEYHGLsXz","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T19:33:53.226045Z","updated_at":"2025-12-25T19:33:53.226045Z","draft_created_at":null,"lead_time":31.38,"prediction":{},"result_count":1,"unique_id":"71f703c1-579c-4773-9362-a9ba577b25df","import_id":null,"last_action":null,"bulk_created":false,"task":15,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":28,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"19 hours, 6 minutes","result":[{"value":{"start":0,"end":62,"text":"Inclusion: 1. Aged 1-12 years with weight≥10kg, male or female","labels":["PATIENT_CRITERIA"]},"id":"Pls_vDOl_3","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":8.453,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T23:01:59.089760Z","updated_at":"2025-12-25T23:01:59.089760Z","task":15,"annotation":15}],"predictions":[],"data":{"text":"Inclusion: 1. Aged 1-12 years with weight≥10kg, male or female;"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T19:33:53.294870Z","allow_skip":true,"inner_id":15,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":16,"annotations":[{"id":16,"completed_by":1,"result":[{"value":{"start":3,"end":129,"text":"The child and\/or guardian has signed the informed consent form (ICF) and has the ability to comply with the study requirements","labels":["PATIENT_CRITERIA"]},"id":"zjOW067yZO","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T19:34:27.391433Z","updated_at":"2025-12-25T19:34:27.391433Z","draft_created_at":null,"lead_time":28.765,"prediction":{},"result_count":1,"unique_id":"815d8961-a9c7-43c0-bdf2-38af4b3d8d78","import_id":null,"last_action":null,"bulk_created":false,"task":16,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"2. The child and\/or guardian has signed the informed consent form (ICF) and has the ability to comply with the study requirements."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T19:34:27.444932Z","allow_skip":true,"inner_id":16,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":17,"annotations":[{"id":17,"completed_by":1,"result":[{"value":{"start":18,"end":51,"text":"relapsed\/refractory neuroblastoma","labels":["CONDITION"]},"id":"XEFHejuS86","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":3,"end":51,"text":"Diagnosed with relapsed\/refractory neuroblastoma","labels":["PATIENT_CRITERIA"]},"id":"LlDDDMess4","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T19:35:44.299584Z","updated_at":"2025-12-25T19:35:44.299584Z","draft_created_at":"2025-12-25T19:35:01.955185Z","lead_time":75.009,"prediction":{},"result_count":2,"unique_id":"5a71db7b-b679-43a8-b1fa-4c3158383ec6","import_id":null,"last_action":null,"bulk_created":false,"task":17,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"3. Diagnosed with relapsed\/refractory neuroblastoma. Clinical diagnostic criteria and first-line standard treatment can refer to the NCCN guidelines:"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T19:35:44.360857Z","allow_skip":true,"inner_id":17,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":18,"annotations":[{"id":18,"completed_by":1,"result":[{"value":{"start":3,"end":25,"text":"Relapsed neuroblastoma","labels":["CONDITION"]},"id":"mYTPaNFTi7","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":27,"end":166,"text":"New lesions appear at the primary site or other locations 4 weeks after achieving complete remission through first-line standard treatment.","labels":["PATIENT_CRITERIA"]},"id":"IUYrz8Wohi","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:04:15.371909Z","updated_at":"2025-12-25T22:04:15.371909Z","draft_created_at":"2025-12-25T19:38:01.386324Z","lead_time":8821.11,"prediction":{},"result_count":2,"unique_id":"8de839d6-b4f4-4479-b7bd-9b6b03b8b8a8","import_id":null,"last_action":null,"bulk_created":false,"task":18,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"1. Relapsed neuroblastoma: New lesions appear at the primary site or other locations 4 weeks after achieving complete remission through first-line standard treatment."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:04:15.419477Z","allow_skip":true,"inner_id":18,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":19,"annotations":[{"id":19,"completed_by":1,"result":[{"value":{"start":3,"end":27,"text":"Refractory neuroblastoma","labels":["CONDITION"]},"id":"qt2mRQMj1G","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":29,"end":224,"text":"Failure to achieve complete remission after standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites","labels":["PATIENT_CRITERIA"]},"id":"WLxDdtZbaS","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:05:05.002165Z","updated_at":"2025-12-25T22:05:05.002165Z","draft_created_at":"2025-12-25T22:04:43.539273Z","lead_time":36.499,"prediction":{},"result_count":2,"unique_id":"3822a37e-d05b-4862-b4ba-451586a9adce","import_id":null,"last_action":null,"bulk_created":false,"task":19,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"2. Refractory neuroblastoma: Failure to achieve complete remission after standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites;"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:05:05.061213Z","allow_skip":true,"inner_id":19,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":20,"annotations":[{"id":20,"completed_by":1,"result":[{"value":{"start":118,"end":140,"text":"partial remission (PR)","labels":["ENDPOINT_TYPE"]},"id":"c_aNMpsb2T","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":144,"end":163,"text":"stable disease (SD)","labels":["ENDPOINT_TYPE"]},"id":"j51mVNfzma","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":3,"end":117,"text":"Prior to enrollment, appropriate measures can be implemented to ensure that the subject's disease status is either","labels":["PATIENT_CRITERIA"]},"id":"DydnWcMg_e","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:07:46.468021Z","updated_at":"2025-12-25T22:07:46.468021Z","draft_created_at":"2025-12-25T22:05:32.170839Z","lead_time":149.873,"prediction":{},"result_count":3,"unique_id":"aab5b4d6-d009-47ff-8e33-db5faee7d830","import_id":null,"last_action":null,"bulk_created":false,"task":20,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"4. Prior to enrollment, appropriate measures can be implemented to ensure that the subject's disease status is either partial remission (PR) or stable disease (SD)."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:07:46.532294Z","allow_skip":true,"inner_id":20,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":21,"annotations":[{"id":21,"completed_by":1,"result":[{"value":{"start":14,"end":319,"text":"According to the INRC efficacy criteria, there must be at least one lesion whose efficacy can be assessed through functional imaging (123I-MIBG) and\/or bone marrow examination (bone marrow aspiration or biopsy). If soft tissue lesions are present, the longest diameter of the target lesion should be ≤2 cm","labels":["PATIENT_CRITERIA"]},"id":"sGVN7KxAKH","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:11:54.110371Z","updated_at":"2025-12-25T22:11:54.110371Z","draft_created_at":"2025-12-25T22:08:31.390018Z","lead_time":245.732,"prediction":{},"result_count":1,"unique_id":"ce873319-7e10-4ff4-ae35-4ab97605389d","import_id":null,"last_action":null,"bulk_created":false,"task":21,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":27,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"19 hours, 6 minutes","result":[{"value":{"start":0,"end":319,"text":"Inclusion: 5. According to the INRC efficacy criteria, there must be at least one lesion whose efficacy can be assessed through functional imaging (123I-MIBG) and\/or bone marrow examination (bone marrow aspiration or biopsy). If soft tissue lesions are present, the longest diameter of the target lesion should be ≤2 cm","labels":["PATIENT_CRITERIA"]},"id":"zU5d5y4w6r","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":9.044,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T23:01:48.042504Z","updated_at":"2025-12-25T23:01:48.042504Z","task":21,"annotation":21}],"predictions":[],"data":{"text":"Inclusion: 5. According to the INRC efficacy criteria, there must be at least one lesion whose efficacy can be assessed through functional imaging (123I-MIBG) and\/or bone marrow examination (bone marrow aspiration or biopsy). If soft tissue lesions are present, the longest diameter of the target lesion should be ≤2 cm."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:11:54.163794Z","allow_skip":true,"inner_id":21,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":22,"annotations":[{"id":22,"completed_by":1,"result":[{"value":{"start":3,"end":153,"text":"Tumor tissue sections or paraffin blocks can be provided, and it has been confirmed through immunohistochemistry (IHC) that the tumor tissue expresses","labels":["PATIENT_CRITERIA"]},"id":"usW0u-iRrL","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":154,"end":159,"text":"B7-H3","labels":["BIOMARKER"]},"id":"qvpyqBVzEd","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:12:45.578164Z","updated_at":"2025-12-25T22:12:45.578164Z","draft_created_at":"2025-12-25T22:12:34.235078Z","lead_time":49.182,"prediction":{},"result_count":2,"unique_id":"acb61fa4-5218-4a3a-9bc9-98efc81e0d8b","import_id":null,"last_action":null,"bulk_created":false,"task":22,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"6. Tumor tissue sections or paraffin blocks can be provided, and it has been confirmed through immunohistochemistry (IHC) that the tumor tissue expresses B7-H3."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:12:45.650474Z","allow_skip":true,"inner_id":22,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":23,"annotations":[{"id":23,"completed_by":1,"result":[{"value":{"start":18,"end":69,"text":"Incidence of Treatment Related adverse events (AEs)","labels":["ENDPOINT"]},"id":"_uTZWXXfZL","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":16,"text":"Primary endpoint","labels":["ENDPOINT_TYPE"]},"id":"JjpqujlHP3","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:34:04.503796Z","updated_at":"2025-12-25T22:34:04.503796Z","draft_created_at":"2025-12-25T22:33:57.084949Z","lead_time":429.223,"prediction":{},"result_count":2,"unique_id":"37274520-e135-4192-90ec-86518d2e303a","import_id":null,"last_action":null,"bulk_created":false,"task":23,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Incidence of Treatment Related adverse events (AEs) [Time Frame: up to 1 year]"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:34:04.578489Z","allow_skip":true,"inner_id":23,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":24,"annotations":[{"id":24,"completed_by":1,"result":[{"value":{"start":45,"end":67,"text":"non-Hodgkin's lymphoma","labels":["CONDITION"]},"id":"WSVLHhwAdb","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":154,"end":164,"text":"bortezomib","labels":["DRUG"]},"id":"F0c-nqwaIk","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":166,"end":175,"text":"rituximab","labels":["DRUG"]},"id":"GjtVQuOCZw","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":180,"end":192,"text":"bendamustine","labels":["DRUG"]},"id":"xDLcc6FdUT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":68,"end":140,"text":"that has not responded to, or that has returned after standard treatment","labels":["PATIENT_CRITERIA"]},"id":"Xxhosoe_-S","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:35:10.395046Z","updated_at":"2025-12-25T22:35:10.395046Z","draft_created_at":"2025-12-25T22:34:21.586901Z","lead_time":64.382,"prediction":{},"result_count":5,"unique_id":"c18c79ed-7f21-476c-96f9-0013b51c72d0","import_id":null,"last_action":null,"bulk_created":false,"task":24,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:35:10.464059Z","allow_skip":true,"inner_id":24,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":25,"annotations":[{"id":25,"completed_by":1,"result":[{"value":{"start":11,"end":251,"text":"Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care","labels":["PATIENT_CRITERIA"]},"id":"6IEvUTfgkg","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:56:38.844993Z","updated_at":"2025-12-25T22:56:38.844993Z","draft_created_at":"2025-12-25T22:42:11.083575Z","lead_time":1165.687,"prediction":{},"result_count":1,"unique_id":"5404fff2-bbe3-4469-a0b8-0080d7f965b5","import_id":null,"last_action":null,"bulk_created":false,"task":25,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":26,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"19 hours, 6 minutes","result":[{"value":{"start":0,"end":251,"text":"Exclusion: Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care","labels":["PATIENT_CRITERIA"]},"id":"dWBz1PDpte","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":10.549,"was_postponed":false,"import_id":null,"created_at":"2025-12-25T23:01:29.840113Z","updated_at":"2025-12-25T23:01:32.470201Z","task":25,"annotation":25}],"predictions":[],"data":{"text":"Exclusion: Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:56:38.894142Z","allow_skip":true,"inner_id":25,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":26,"annotations":[{"id":26,"completed_by":1,"result":[{"value":{"start":0,"end":140,"text":"Female subject is either post-menopausal or surgically sterilized or willing to use acceptable method of birth control for duration of study","labels":["PATIENT_CRITERIA"]},"id":"b0T_5q_99b","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:57:21.780671Z","updated_at":"2025-12-25T22:57:21.780671Z","draft_created_at":null,"lead_time":39.077,"prediction":{},"result_count":1,"unique_id":"51af093e-6024-45a5-979b-a04dc3bbf4f3","import_id":null,"last_action":null,"bulk_created":false,"task":26,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Female subject is either post-menopausal or surgically sterilized or willing to use acceptable method of birth control for duration of study."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:57:21.838439Z","allow_skip":true,"inner_id":26,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":27,"annotations":[{"id":27,"completed_by":1,"result":[{"value":{"start":0,"end":84,"text":"Male subject agrees to use acceptable method for contraception for duration of study","labels":["PATIENT_CRITERIA"]},"id":"beqPe825Ig","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T22:58:23.549123Z","updated_at":"2025-12-25T22:58:23.549123Z","draft_created_at":"2025-12-25T22:57:37.145449Z","lead_time":60.09,"prediction":{},"result_count":1,"unique_id":"cc557f94-6ffc-4baa-aeea-e8c5d512bc91","import_id":null,"last_action":null,"bulk_created":false,"task":27,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Male subject agrees to use acceptable method for contraception for duration of study."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T22:58:23.613755Z","allow_skip":true,"inner_id":27,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":28,"annotations":[{"id":28,"completed_by":1,"result":[{"value":{"start":36,"end":68,"text":"indolent or mantle cell lymphoma","labels":["CONDITION"]},"id":"e6jTWAS8-G","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":185,"text":"Inclusion: Histologically-confirmed indolent or mantle cell lymphoma, utilizing the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria","labels":["PATIENT_CRITERIA"]},"id":"aQg80JXIh5","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-25T23:01:18.380429Z","updated_at":"2025-12-25T23:01:18.380429Z","draft_created_at":"2025-12-25T22:59:07.124616Z","lead_time":173.567,"prediction":{},"result_count":2,"unique_id":"0759df3d-1c82-4a28-913b-96c2865604e2","import_id":null,"last_action":null,"bulk_created":false,"task":28,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Histologically-confirmed indolent or mantle cell lymphoma, utilizing the World Health Organization (WHO) classification. The biopsy must fulfill one of the following criteria:"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-25T23:01:18.445336Z","allow_skip":true,"inner_id":28,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":29,"annotations":[{"id":29,"completed_by":1,"result":[{"value":{"start":0,"end":19,"text":"Follicular lymphoma","labels":["CONDITION"]},"id":"NwKOe7obH0","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":21,"end":31,"text":"grades 1-3","labels":["PATIENT_CRITERIA"]},"id":"ZFoKuLm3Qp","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T00:38:44.405137Z","updated_at":"2025-12-26T00:38:44.405137Z","draft_created_at":"2025-12-26T00:38:39.260913Z","lead_time":5673.887,"prediction":{},"result_count":2,"unique_id":"4ed40f2e-9f71-425d-957c-1caacc0c137e","import_id":null,"last_action":null,"bulk_created":false,"task":29,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Follicular lymphoma, grades 1-3"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T00:38:44.460341Z","allow_skip":true,"inner_id":29,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":30,"annotations":[{"id":30,"completed_by":1,"result":[{"value":{"start":11,"end":37,"text":"Small lymphocytic lymphoma","labels":["CONDITION"]},"id":"jCYP1h5I_U","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":0,"end":85,"text":"Inclusion: Small lymphocytic lymphoma (circulating lymphocyte count must be \\< 5,000)","labels":["PATIENT_CRITERIA"]},"id":"UGkwWmXAlF","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T00:41:37.297940Z","updated_at":"2025-12-26T00:41:37.297940Z","draft_created_at":"2025-12-26T00:39:14.087829Z","lead_time":171.26,"prediction":{},"result_count":2,"unique_id":"f7445ee8-cbb9-471e-9b19-bff029be72d4","import_id":null,"last_action":null,"bulk_created":false,"task":30,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Small lymphocytic lymphoma (circulating lymphocyte count must be \\< 5,000)"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T00:41:37.365147Z","allow_skip":true,"inner_id":30,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":31,"annotations":[{"id":31,"completed_by":1,"result":[{"value":{"start":0,"end":20,"text":"Mantle cell lymphoma","labels":["CONDITION"]},"id":"EoZpefy5lK","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":23,"end":67,"text":"confirmed by cyclin D1+ or FISH for t(11;14)","labels":["PATIENT_CRITERIA"]},"id":"sOLsSG6tjj","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T00:43:00.269041Z","updated_at":"2025-12-26T00:43:00.269041Z","draft_created_at":"2025-12-26T00:42:50.502381Z","lead_time":81.536,"prediction":{},"result_count":2,"unique_id":"10de9f77-d1e1-4565-b22f-88022437ebbd","import_id":null,"last_action":null,"bulk_created":false,"task":31,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Mantle cell lymphoma \\[confirmed by cyclin D1+ or FISH for t(11;14)\\]"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T00:43:00.325571Z","allow_skip":true,"inner_id":31,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":32,"annotations":[{"id":32,"completed_by":1,"result":[{"value":{"start":0,"end":175,"text":"Inclusion: Must have received at least one prior chemotherapy regimen for lymphoma. Patients treated only with antibody therapy or only with radiation therapy are not eligible","labels":["PATIENT_CRITERIA"]},"id":"Paf7XIuSrn","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T00:44:02.890704Z","updated_at":"2025-12-26T00:44:02.890704Z","draft_created_at":"2025-12-26T00:43:25.515388Z","lead_time":58.2,"prediction":{},"result_count":1,"unique_id":"e249f1fd-5423-4cd9-a5fd-8b67f7e6807e","import_id":null,"last_action":null,"bulk_created":false,"task":32,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Must have received at least one prior chemotherapy regimen for lymphoma. Patients treated only with antibody therapy or only with radiation therapy are not eligible."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T00:44:02.941439Z","allow_skip":true,"inner_id":32,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":33,"annotations":[{"id":33,"completed_by":1,"result":[{"value":{"start":0,"end":16,"text":"Primary endpoint","labels":["ENDPOINT_TYPE"]},"id":"EPM-34JJSa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":18,"end":71,"text":"Number of Participants With Progression Free Survival","labels":["ENDPOINT"]},"id":"qddR4p3GI6","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:01:03.753047Z","updated_at":"2025-12-26T01:01:03.753047Z","draft_created_at":"2025-12-26T00:44:17.080083Z","lead_time":1019.391,"prediction":{},"result_count":2,"unique_id":"4c6a90a9-6f14-4e3f-a9a1-5152d7857f26","import_id":null,"last_action":null,"bulk_created":false,"task":33,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[{"id":43,"user":"panwarnalini@gmail.com","created_username":"Nalini Panwar panwarnalini@gmail.com, 1","created_ago":"10 hours, 15 minutes","result":[{"value":{"start":18,"end":71,"text":"Number of Participants With Progression Free Survival","labels":["ENDPOINT"]},"id":"qddR4p3GI6","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"lead_time":88.498,"was_postponed":false,"import_id":null,"created_at":"2025-12-26T07:52:52.887804Z","updated_at":"2025-12-26T07:52:52.887804Z","task":33,"annotation":33}],"predictions":[],"data":{"text":"Primary endpoint: Number of Participants With Progression Free Survival at 2 Years [Time Frame: Two years]"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:01:03.807302Z","allow_skip":true,"inner_id":33,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":34,"annotations":[{"id":34,"completed_by":1,"result":[{"value":{"start":6,"end":17,"text":"bortezomib ","labels":["DRUG"]},"id":"BpR4g-dMwR","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":19,"end":50,"text":"1.3 mg\/m\\^2 on days 1, 4, 8, 11","labels":["DOSAGE"]},"id":"G6FIvTMpv_","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:05:11.500469Z","updated_at":"2025-12-26T01:05:11.501468Z","draft_created_at":"2025-12-26T01:03:44.085584Z","lead_time":245.539,"prediction":{},"result_count":2,"unique_id":"6e22e9a8-0887-4e0b-9bea-691e219de072","import_id":null,"last_action":null,"bulk_created":false,"task":34,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"DRUG: bortezomib - 1.3 mg\/m\\^2 on days 1, 4, 8, 11"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:05:11.572817Z","allow_skip":true,"inner_id":34,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":35,"annotations":[{"id":35,"completed_by":1,"result":[{"value":{"start":5,"end":14,"text":"phase III","labels":["STUDY_PHASE"]},"id":"R_xuZ5NpMU","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":118,"end":134,"text":"multiple myeloma","labels":["CONDITION"]},"id":"yNVG8eIWaU","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":104,"end":197,"text":"patients with multiple myeloma who have received primary induction therapy or other therapies","labels":["PATIENT_CRITERIA"]},"id":"FMufvt1qPm","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:09:43.132511Z","updated_at":"2025-12-26T01:09:43.132511Z","draft_created_at":"2025-12-26T01:08:35.083025Z","lead_time":213.55,"prediction":{},"result_count":3,"unique_id":"cf6bc6d7-9567-472d-ab4d-5549b73e3063","import_id":null,"last_action":null,"bulk_created":false,"task":35,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:09:43.198843Z","allow_skip":true,"inner_id":35,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":36,"annotations":[{"id":36,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:10:06.889612Z","updated_at":"2025-12-26T01:10:06.889612Z","draft_created_at":null,"lead_time":21.006,"prediction":{},"result_count":0,"unique_id":"0be38345-9149-47ad-a9c7-06a35dc6d0ca","import_id":null,"last_action":null,"bulk_created":false,"task":36,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Up to 180 patients will be enrolled."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:10:06.969748Z","allow_skip":true,"inner_id":36,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":37,"annotations":[{"id":37,"completed_by":1,"result":[{"value":{"start":113,"end":120,"text":"VELCADE","labels":["DRUG"]},"id":"BIs0AENain","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":122,"end":138,"text":"CYCLOPHOSPHAMIDE","labels":["DRUG"]},"id":"EECEhrqwKd","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":216,"end":226,"text":"PLERIXAFOR","labels":["DRUG"]},"id":"DCHx_Ricg8","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":143,"end":148,"text":"G-CSF","labels":["DRUG"]},"id":"CKebouCknp","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:16:04.312344Z","updated_at":"2025-12-26T01:16:04.312344Z","draft_created_at":"2025-12-26T01:13:14.273499Z","lead_time":279.814,"prediction":{},"result_count":4,"unique_id":"332f9e53-cc45-43cc-947c-2cfbda67170d","import_id":null,"last_action":null,"bulk_created":false,"task":37,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Patients eligible for treatment will be randomized to one of the three following mobilization regimens:\n\nArm A = VELCADE, CYCLOPHOSPHAMIDE, \\& G-CSF Arm B = VELCADE \\& G-CSF Arm C = CYCLOPHOSPHAMIDE \\& G-CSF Arm D = PLERIXAFOR \\& G-CSF Arm E = PLERIXAFOR, VELCADE, \\& G-CSF"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:16:04.375966Z","allow_skip":true,"inner_id":37,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":38,"annotations":[{"id":38,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:17:24.313934Z","updated_at":"2025-12-26T01:17:24.313934Z","draft_created_at":null,"lead_time":77.816,"prediction":{},"result_count":0,"unique_id":"b3fca325-ad5d-4210-9b72-244763435301","import_id":null,"last_action":null,"bulk_created":false,"task":38,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"PRIMARY STUDY OBJECTIVES\n\n• To compare the efficacy of the following peripheral stem cell mobilization regimens for MM: i."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:17:24.374222Z","allow_skip":true,"inner_id":38,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":39,"annotations":[{"id":39,"completed_by":1,"result":[{"value":{"start":10,"end":26,"text":"cyclophosphamide","labels":["DRUG"]},"id":"jcrUP39nRH","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":28,"end":35,"text":"VELCADE","labels":["DRUG"]},"id":"npKglaWeG1","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":41,"end":46,"text":"G-CSF","labels":["DRUG"]},"id":"q7Sf2FsOAk","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:18:03.226295Z","updated_at":"2025-12-26T01:18:03.226295Z","draft_created_at":"2025-12-26T01:17:39.192443Z","lead_time":33.881,"prediction":{},"result_count":3,"unique_id":"53183667-e623-4e50-ac92-855c9033115f","import_id":null,"last_action":null,"bulk_created":false,"task":39,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"High dose cyclophosphamide, VELCADE, and G-CSF ii."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:18:03.286325Z","allow_skip":true,"inner_id":39,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":40,"annotations":[{"id":40,"completed_by":1,"result":[{"value":{"start":10,"end":27,"text":"cyclophosphamide ","labels":["DRUG"]},"id":"gDdKPLaLPa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":31,"end":36,"text":"G-CSF","labels":["DRUG"]},"id":"Yr9_jGAnyK","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:26:09.433509Z","updated_at":"2025-12-26T01:26:09.433509Z","draft_created_at":"2025-12-26T01:18:19.009355Z","lead_time":478.612,"prediction":{},"result_count":2,"unique_id":"cb0256a3-c700-4c71-af84-a4fd2c9d3c16","import_id":null,"last_action":null,"bulk_created":false,"task":40,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"High dose cyclophosphamide and G-CSF\n\nSECONDARY STUDY OBJECTIVES\n\n• To evaluate biomarkers as surrogate markers of mobilization in each arm To evaluate changes in tumor mass as defined by standard response parameters."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:26:09.525133Z","allow_skip":true,"inner_id":40,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":41,"annotations":[{"id":41,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:42:18.605127Z","updated_at":"2025-12-26T01:42:18.605127Z","draft_created_at":null,"lead_time":967.331,"prediction":{},"result_count":0,"unique_id":"710f5b5b-04a6-4459-b791-cf6a7f52085d","import_id":null,"last_action":null,"bulk_created":false,"task":41,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"To evaluate the safety of each of the arms."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:42:18.655129Z","allow_skip":true,"inner_id":41,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":42,"annotations":[{"id":42,"completed_by":1,"result":[{"value":{"start":0,"end":34,"text":"Voluntary written informed consent","labels":["PATIENT_CRITERIA"]},"id":"DLvAAQaDaY","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T01:42:52.752982Z","updated_at":"2025-12-26T01:42:52.752982Z","draft_created_at":null,"lead_time":32.165,"prediction":{},"result_count":1,"unique_id":"70c7aa1c-99ce-49bd-80a9-21ec2731b88f","import_id":null,"last_action":null,"bulk_created":false,"task":42,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Voluntary written informed consent"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T01:42:52.812997Z","allow_skip":true,"inner_id":42,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":43,"annotations":[{"id":43,"completed_by":1,"result":[{"value":{"start":0,"end":50,"text":"Inclusion: Confirmed diagnosis of multiple myeloma","labels":["PATIENT_CRITERIA"]},"id":"_IE6kM_kjC","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":34,"end":50,"text":"multiple myeloma","labels":["CONDITION"]},"id":"UpM3Fq39-e","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T02:09:14.033498Z","updated_at":"2025-12-26T02:09:14.033498Z","draft_created_at":"2025-12-26T01:45:25.174374Z","lead_time":1441.82,"prediction":{},"result_count":2,"unique_id":"19a55289-ddfa-424c-8bb1-ead16d781761","import_id":null,"last_action":null,"bulk_created":false,"task":43,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Confirmed diagnosis of multiple myeloma"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T02:09:14.101070Z","allow_skip":true,"inner_id":43,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":44,"annotations":[{"id":44,"completed_by":1,"result":[{"value":{"start":0,"end":31,"text":"Inclusion: Age \\> than 18 years","labels":["PATIENT_CRITERIA"]},"id":"qKto2zuVGP","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T06:04:53.324596Z","updated_at":"2025-12-26T06:04:53.324596Z","draft_created_at":"2025-12-26T06:04:51.073548Z","lead_time":14137.846,"prediction":{},"result_count":1,"unique_id":"77b13cb5-b7f5-4f59-a5b2-96c540c83d09","import_id":null,"last_action":null,"bulk_created":false,"task":44,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Age \\> than 18 years at the time of signing the informed consent form."},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T06:04:53.380600Z","allow_skip":true,"inner_id":44,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":45,"annotations":[{"id":45,"completed_by":1,"result":[{"value":{"start":18,"end":97,"text":"Number of Patients Able to Collect >=6 x 106 CD34+ Cells\/kg in <= 2 Collections","labels":["ENDPOINT"]},"id":"DeB7udWI_A","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T07:53:04.442821Z","updated_at":"2025-12-26T08:42:35.078088Z","draft_created_at":"2025-12-26T06:05:09.705041Z","lead_time":4096.588,"prediction":{},"result_count":1,"unique_id":"d5879f53-5de8-43f9-a39d-9649f866c50c","import_id":null,"last_action":null,"bulk_created":false,"task":45,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Number of Patients Able to Collect >=6 x 106 CD34+ Cells\/kg in <= 2 Collections. [Time Frame: 36 months]"},"meta":{},"created_at":"2025-12-25T17:15:25.257785Z","updated_at":"2025-12-26T08:42:35.135089Z","allow_skip":true,"inner_id":45,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":46,"annotations":[{"id":46,"completed_by":1,"result":[{"value":{"start":6,"end":26,"text":"bortezomib (Velcade)","labels":["DRUG"]},"id":"VqO3Xnunx2","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":29,"end":65,"text":"1.3 mg\/m2 IVP on days 1, 4, 8 and 11","labels":["DOSAGE"]},"id":"z_UE4LTHc-","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:43:16.064215Z","updated_at":"2025-12-26T08:43:16.064215Z","draft_created_at":"2025-12-26T08:43:11.126705Z","lead_time":37.155,"prediction":{},"result_count":2,"unique_id":"650c65c7-0e27-457e-a0e8-822cfa2f5fd0","import_id":null,"last_action":null,"bulk_created":false,"task":46,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"DRUG: bortezomib (Velcade) - 1.3 mg\/m2 IVP on days 1, 4, 8 and 11"},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:43:16.109214Z","allow_skip":true,"inner_id":46,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":47,"annotations":[{"id":47,"completed_by":1,"result":[{"value":{"start":232,"end":305,"text":"refractory\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)","labels":["CONDITION"]},"id":"NAoaBa5a9L","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":90,"end":104,"text":"pembrolizumab ","labels":["DRUG"]},"id":"cc7CaYeR5k","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":142,"end":161,"text":"5-fluorouracil (FU)","labels":["DRUG"]},"id":"OksoOnRlbT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":63,"end":75,"text":"amivantamab ","labels":["DRUG"]},"id":"a8TZNbMSqd","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":108,"end":120,"text":"carboplatin ","labels":["DRUG"]},"id":"Q4Uv_Rn7L8","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":127,"end":140,"text":"pembrolizumab","labels":["DRUG"]},"id":"p799L2JpPK","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":200,"end":209,"text":"cisplatin","labels":["DRUG"]},"id":"zqUHk0cCKk","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":185,"end":197,"text":"carboplatin ","labels":["DRUG"]},"id":"D6rJV-fcu0","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:44:44.995459Z","updated_at":"2025-12-26T08:44:44.995459Z","draft_created_at":"2025-12-26T08:43:59.729317Z","lead_time":86.979,"prediction":{},"result_count":8,"unique_id":"f21af9fe-394e-4d68-87da-841e642e6e19","import_id":null,"last_action":null,"bulk_created":false,"task":47,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)."},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:44:45.046456Z","allow_skip":true,"inner_id":47,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":48,"annotations":[{"id":48,"completed_by":1,"result":[{"value":{"start":0,"end":6,"text":"HNSCC ","labels":["CONDITION"]},"id":"k8PKfiZacs","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:45:22.053058Z","updated_at":"2025-12-26T08:45:22.053058Z","draft_created_at":null,"lead_time":10.632,"prediction":{},"result_count":1,"unique_id":"76015134-f3d5-44a9-ad3d-1c3699823e83","import_id":null,"last_action":null,"bulk_created":false,"task":48,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat."},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:45:22.109067Z","allow_skip":true,"inner_id":48,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":49,"annotations":[{"id":49,"completed_by":1,"result":[{"value":{"start":43,"end":49,"text":"HNSCC ","labels":["CONDITION"]},"id":"Fkdb6AQnuT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":57,"end":72,"text":"treatment-naive","labels":["PATIENT_CRITERIA"]},"id":"Uou1pgu0Kj","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:46:37.286800Z","updated_at":"2025-12-26T08:46:37.286800Z","draft_created_at":"2025-12-26T08:45:32.071101Z","lead_time":73.717,"prediction":{},"result_count":2,"unique_id":"fc304fff-8b0a-4edb-9c50-f3a67af9ad7f","import_id":null,"last_action":null,"bulk_created":false,"task":49,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R\/M setting."},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:46:37.322799Z","allow_skip":true,"inner_id":49,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":50,"annotations":[{"id":50,"completed_by":1,"result":[{"value":{"start":0,"end":165,"text":"Inclusion: Be more than or equal to (\\>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater)","labels":["PATIENT_CRITERIA"]},"id":"PNaazhpvUb","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:47:08.764887Z","updated_at":"2025-12-26T08:47:08.764887Z","draft_created_at":null,"lead_time":28.503,"prediction":{},"result_count":1,"unique_id":"2973349b-78d6-47b8-8df9-8c8f7a2fe2f9","import_id":null,"last_action":null,"bulk_created":false,"task":50,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Be more than or equal to (\\>=) 18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place, whichever is greater)"},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:47:08.797888Z","allow_skip":true,"inner_id":50,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":51,"annotations":[{"id":51,"completed_by":1,"result":[{"value":{"start":0,"end":58,"text":"Be treatment-naive for systemic therapy in the R\/M setting","labels":["PATIENT_CRITERIA"]},"id":"YEPI18adVS","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:47:32.720970Z","updated_at":"2025-12-26T08:47:32.720970Z","draft_created_at":null,"lead_time":22.66,"prediction":{},"result_count":1,"unique_id":"c729341a-2ed5-41b1-a938-c2a0d4d9fc65","import_id":null,"last_action":null,"bulk_created":false,"task":51,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Be treatment-naive for systemic therapy in the R\/M setting"},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:47:32.751970Z","allow_skip":true,"inner_id":51,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":52,"annotations":[{"id":52,"completed_by":1,"result":[{"value":{"start":0,"end":41,"text":"Have an ECOG performance status of 0 or 1","labels":["PATIENT_CRITERIA"]},"id":"YpScmltdTm","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:47:56.002030Z","updated_at":"2025-12-26T08:47:56.002030Z","draft_created_at":null,"lead_time":20.257,"prediction":{},"result_count":1,"unique_id":"a3d08022-3b0e-4b28-9dfd-aa04af06cb5c","import_id":null,"last_action":null,"bulk_created":false,"task":52,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have an ECOG performance status of 0 or 1"},"meta":{},"created_at":"2025-12-25T17:15:25.258785Z","updated_at":"2025-12-26T08:47:56.035032Z","allow_skip":true,"inner_id":52,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":53,"annotations":[{"id":53,"completed_by":1,"result":[{"value":{"start":0,"end":106,"text":"Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1","labels":["PATIENT_CRITERIA"]},"id":"GlZGpK2jpL","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:50:19.610314Z","updated_at":"2025-12-26T08:50:19.610314Z","draft_created_at":null,"lead_time":141.978,"prediction":{},"result_count":1,"unique_id":"afecd249-a731-43c7-aec2-f470d62c52b6","import_id":null,"last_action":null,"bulk_created":false,"task":53,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1"},"meta":{},"created_at":"2025-12-25T17:15:25.262785Z","updated_at":"2025-12-26T08:50:19.658314Z","allow_skip":true,"inner_id":53,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":54,"annotations":[{"id":54,"completed_by":1,"result":[{"value":{"start":0,"end":86,"text":"Have untreated brain metastases or history of known presence of leptomeningeal disease","labels":["PATIENT_CRITERIA"]},"id":"JIJylAndQY","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:51:04.204465Z","updated_at":"2025-12-26T08:51:04.204465Z","draft_created_at":"2025-12-26T08:50:33.382365Z","lead_time":43.278,"prediction":{},"result_count":1,"unique_id":"4535f846-8020-48dd-9b18-2665579477f3","import_id":null,"last_action":null,"bulk_created":false,"task":54,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have untreated brain metastases or history of known presence of leptomeningeal disease"},"meta":{},"created_at":"2025-12-25T17:15:25.262785Z","updated_at":"2025-12-26T08:51:04.248465Z","allow_skip":true,"inner_id":54,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":55,"annotations":[{"id":55,"completed_by":1,"result":[{"value":{"start":0,"end":63,"text":"Have a history of clinically significant cardiovascular disease","labels":["PATIENT_CRITERIA"]},"id":"GsxKUWv4JH","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:51:16.916483Z","updated_at":"2025-12-26T08:51:16.916483Z","draft_created_at":null,"lead_time":11.42,"prediction":{},"result_count":1,"unique_id":"89203f23-343e-411a-b1d4-1567a2f5eff7","import_id":null,"last_action":null,"bulk_created":false,"task":55,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have a history of clinically significant cardiovascular disease"},"meta":{},"created_at":"2025-12-25T17:15:25.262785Z","updated_at":"2025-12-26T08:51:16.950483Z","allow_skip":true,"inner_id":55,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":56,"annotations":[{"id":56,"completed_by":1,"result":[{"value":{"start":18,"end":39,"text":"Overall Survival (OS)","labels":["ENDPOINT"]},"id":"s8JyfuJJIO","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:51:45.573564Z","updated_at":"2025-12-26T08:51:45.573564Z","draft_created_at":null,"lead_time":26.956,"prediction":{},"result_count":1,"unique_id":"f7109cfb-0aa2-4b3d-aa4d-052a776fd3a7","import_id":null,"last_action":null,"bulk_created":false,"task":56,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Overall Survival (OS) [Time Frame: Up to approximately 3 years 7 months]"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:51:45.605565Z","allow_skip":true,"inner_id":56,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":57,"annotations":[{"id":57,"completed_by":1,"result":[{"value":{"start":18,"end":47,"text":"Objective Response Rate (ORR)","labels":["ENDPOINT"]},"id":"p3adgvyJCb","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:53:11.664262Z","updated_at":"2025-12-26T08:53:11.664262Z","draft_created_at":"2025-12-26T08:52:19.956637Z","lead_time":84.815,"prediction":{},"result_count":1,"unique_id":"e4f48f73-a8a5-40be-a12d-da067e682063","import_id":null,"last_action":null,"bulk_created":false,"task":57,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) [Time Frame: Up to approximately 3 years 7 months]"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:53:11.706263Z","allow_skip":true,"inner_id":57,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":58,"annotations":[{"id":58,"completed_by":1,"result":[{"value":{"start":5,"end":15,"text":"phase I\/II","labels":["STUDY_PHASE"]},"id":"J5n2QlFvWY","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":39,"end":53,"text":"pembrolizumab ","labels":["DRUG"]},"id":"i9l-RT0V0-","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":57,"end":69,"text":"carboplatin ","labels":["DRUG"]},"id":"R8Lj4S8KMR","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":100,"end":107,"text":"ovarian","labels":["CONDITION"]},"id":"SdWLgtaLBI","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":174,"end":182,"text":"relapsed","labels":["PATIENT_CRITERIA"]},"id":"xTI8jKt9Jv","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":228,"end":238,"text":"refractory","labels":["PATIENT_CRITERIA"]},"id":"zZnLIkOjDw","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":109,"end":123,"text":"fallopian tube","labels":["CONDITION"]},"id":"d5muVwcCaL","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":128,"end":154,"text":"primary peritoneal cancer ","labels":["CONDITION"]},"id":"MF5Vc__lWA","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:55:14.087114Z","updated_at":"2025-12-26T08:55:14.087114Z","draft_created_at":"2025-12-26T08:53:39.673869Z","lead_time":120.743,"prediction":{},"result_count":8,"unique_id":"72a902cf-38b9-4967-9b74-49471fa0b113","import_id":null,"last_action":null,"bulk_created":false,"task":58,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This phase I\/II trial studies how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (relapsed) or has not responded to previous treatment (refractory)."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:55:14.156114Z","allow_skip":true,"inner_id":58,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":59,"annotations":[{"id":59,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:56:50.004312Z","updated_at":"2025-12-26T08:56:50.004312Z","draft_created_at":null,"lead_time":86.91,"prediction":{},"result_count":0,"unique_id":"3361c393-2bbd-474b-b1a1-5147ce6ecbe5","import_id":null,"last_action":null,"bulk_created":false,"task":59,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:56:50.033313Z","allow_skip":true,"inner_id":59,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":60,"annotations":[{"id":60,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:57:16.213399Z","updated_at":"2025-12-26T08:57:16.213399Z","draft_created_at":null,"lead_time":24.766,"prediction":{},"result_count":0,"unique_id":"32ae4d1f-0cef-484c-91a8-2927864b49b2","import_id":null,"last_action":null,"bulk_created":false,"task":60,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:57:16.255398Z","allow_skip":true,"inner_id":60,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":61,"annotations":[{"id":61,"completed_by":1,"result":[{"value":{"start":7,"end":21,"text":"pembrolizumab ","labels":["DRUG"]},"id":"NrNhe6oo7v","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":25,"end":37,"text":"carboplatin ","labels":["DRUG"]},"id":"0LnffsvzKM","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":149,"end":156,"text":"ovarian","labels":["CONDITION"]},"id":"ayuRPX5ZrM","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":158,"end":172,"text":"fallopian tube","labels":["CONDITION"]},"id":"kbkbYvxdpA","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":177,"end":202,"text":"primary peritoneal cancer","labels":["CONDITION"]},"id":"v8msunty8F","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T08:58:55.847893Z","updated_at":"2025-12-26T08:58:55.847893Z","draft_created_at":"2025-12-26T08:58:21.541487Z","lead_time":81.137,"prediction":{},"result_count":5,"unique_id":"5992bfde-0eb0-43ef-ad56-e57f94adce5b","import_id":null,"last_action":null,"bulk_created":false,"task":61,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Giving pembrolizumab and carboplatin with platinum resistant chemotherapy may work better than platinum chemotherapy alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T08:58:55.886969Z","allow_skip":true,"inner_id":61,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":62,"annotations":[{"id":62,"completed_by":1,"result":[{"value":{"start":17,"end":39,"text":"clinical response rate","labels":["ENDPOINT"]},"id":"f0ZBtrb5Fr","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":69,"end":83,"text":"pembrolizumab ","labels":["DRUG"]},"id":"g9SKKLGIuE","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":96,"end":128,"text":"platinum chemotherapy pretreated","labels":["PATIENT_CRITERIA"]},"id":"8hJ6Wkaeoa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":129,"end":176,"text":"ovarian, fallopian tube, and primary peritoneal","labels":["CONDITION"]},"id":"yICbqVINBT","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:00:23.939107Z","updated_at":"2025-12-26T09:01:25.674255Z","draft_created_at":"2025-12-26T08:59:21.303460Z","lead_time":92.666,"prediction":{},"result_count":4,"unique_id":"c6a1a21d-6df7-4acd-a0cf-b827474b0e15","import_id":null,"last_action":null,"bulk_created":false,"task":62,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"To determine the clinical response rate of platinum chemotherapy and pembrolizumab (MK-3475) in platinum chemotherapy pretreated ovarian, fallopian tube, and primary peritoneal."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:01:25.719256Z","allow_skip":true,"inner_id":62,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":63,"annotations":[{"id":63,"completed_by":1,"result":[{"value":{"start":145,"end":170,"text":"progression free survival","labels":["ENDPOINT"]},"id":"cE2Aofcl8o","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":203,"end":210,"text":"MK-3475","labels":["DRUG"]},"id":"DxP3ojZ-qT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":61,"end":135,"text":"platinum resistant ovarian, fallopian tube, and primary peritoneal cancers","labels":["CONDITION"]},"id":"Y9eq9FbJ1I","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:02:25.513426Z","updated_at":"2025-12-26T09:02:25.513426Z","draft_created_at":"2025-12-26T09:02:04.269378Z","lead_time":47.853,"prediction":{},"result_count":3,"unique_id":"45697f22-9988-4246-81a7-c1535d9a8449","import_id":null,"last_action":null,"bulk_created":false,"task":63,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"To examine whether retreatment with platinum chemotherapy in platinum resistant ovarian, fallopian tube, and primary peritoneal cancers improves progression free survival by concurrent administration of MK-3475."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:02:25.557427Z","allow_skip":true,"inner_id":63,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":64,"annotations":[{"id":64,"completed_by":1,"result":[{"value":{"start":0,"end":323,"text":"Inclusion: Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer patients who had a complete response to primary treatment with platinum based chemotherapy, have progressed within 6 months of completing platinum based chemotherapy and have subsequently received at least one, non-platinum-based, therapy","labels":["PATIENT_CRITERIA"]},"id":"MhSoY7FFuw","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":31,"end":38,"text":"ovarian","labels":["CONDITION"]},"id":"86A55rypQr","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":40,"end":55,"text":"fallopian tube,","labels":["CONDITION"]},"id":"cM9ydVxnG7","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":59,"end":84,"text":"primary peritoneal cancer","labels":["CONDITION"]},"id":"qGKeB4Id6D","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:05:21.348354Z","updated_at":"2025-12-26T09:05:21.348354Z","draft_created_at":"2025-12-26T09:03:24.074592Z","lead_time":158.251,"prediction":{},"result_count":4,"unique_id":"ff026d6a-be58-4203-a6ff-0195cd81b9c3","import_id":null,"last_action":null,"bulk_created":false,"task":64,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer patients who had a complete response to primary treatment with platinum based chemotherapy, have progressed within 6 months of completing platinum based chemotherapy and have subsequently received at least one, non-platinum-based, therapy"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:05:21.397354Z","allow_skip":true,"inner_id":64,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":65,"annotations":[{"id":65,"completed_by":1,"result":[{"value":{"start":0,"end":82,"text":"Have relapsed, refractory, or progressive disease following last line of treatment","labels":["PATIENT_CRITERIA"]},"id":"kU92eM_phS","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:05:46.177924Z","updated_at":"2025-12-26T09:05:46.177924Z","draft_created_at":"2025-12-26T09:05:45.305924Z","lead_time":23.189,"prediction":{},"result_count":1,"unique_id":"e42ae6ad-9544-4304-b1d5-cda3873c7ceb","import_id":null,"last_action":null,"bulk_created":false,"task":65,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have relapsed, refractory, or progressive disease following last line of treatment"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:05:46.212924Z","allow_skip":true,"inner_id":65,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":66,"annotations":[{"id":66,"completed_by":1,"result":[{"value":{"start":0,"end":51,"text":"Have estimated life expectancy of at least 3 months","labels":["PATIENT_CRITERIA"]},"id":"A_ddTKxZWz","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:05:56.856946Z","updated_at":"2025-12-26T09:05:56.856946Z","draft_created_at":null,"lead_time":8.132,"prediction":{},"result_count":1,"unique_id":"d7e6e5cd-8d70-4c5b-80e4-960204f3b5cb","import_id":null,"last_action":null,"bulk_created":false,"task":66,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Have estimated life expectancy of at least 3 months"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:05:56.887947Z","allow_skip":true,"inner_id":66,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":67,"annotations":[{"id":67,"completed_by":1,"result":[{"value":{"start":0,"end":76,"text":"Be willing and able to provide written informed consent\/assent for the trial","labels":["PATIENT_CRITERIA"]},"id":"hQR-4hhgDb","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:06:09.516975Z","updated_at":"2025-12-26T09:06:09.516975Z","draft_created_at":null,"lead_time":11.608,"prediction":{},"result_count":1,"unique_id":"6aa84f10-1bf5-4111-8475-174917233b41","import_id":null,"last_action":null,"bulk_created":false,"task":67,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Be willing and able to provide written informed consent\/assent for the trial"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:06:09.548972Z","allow_skip":true,"inner_id":67,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":68,"annotations":[{"id":68,"completed_by":1,"result":[{"value":{"start":18,"end":36,"text":"Response Rate (RR)","labels":["ENDPOINT"]},"id":"65cnSOc1XH","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:06:33.366062Z","updated_at":"2025-12-26T09:06:33.366062Z","draft_created_at":null,"lead_time":22.439,"prediction":{},"result_count":1,"unique_id":"48e59cd5-5ed4-4434-afdb-041605dcccf2","import_id":null,"last_action":null,"bulk_created":false,"task":68,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [Time Frame: 6 months]"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:06:33.409064Z","allow_skip":true,"inner_id":68,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":69,"annotations":[{"id":69,"completed_by":1,"result":[{"value":{"start":18,"end":49,"text":"Progression-free Survival (PFS)","labels":["ENDPOINT"]},"id":"ujQ-lLyp9p","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:07:03.494142Z","updated_at":"2025-12-26T09:07:03.494142Z","draft_created_at":null,"lead_time":29.074,"prediction":{},"result_count":1,"unique_id":"41fc9910-cf17-4c8c-bc37-f84b317620b4","import_id":null,"last_action":null,"bulk_created":false,"task":69,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Progression-free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [Time Frame: 6 months]"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:07:03.524142Z","allow_skip":true,"inner_id":69,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":70,"annotations":[{"id":70,"completed_by":1,"result":[{"value":{"start":88,"end":110,"text":"advanced breast cancer","labels":["CONDITION"]},"id":"AvFXs-4AFa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":184,"end":195,"text":"HR+ \/ HER2-","labels":["PATIENT_CRITERIA"]},"id":"BS9iAKFScS","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":296,"end":317,"text":"palbociclib (Ibrance)","labels":["DRUG"]},"id":"2lCFlmSnTd","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":244,"end":255,"text":"fulvestrant","labels":["DRUG"]},"id":"vQDK51xIHa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":221,"end":240,"text":"aromatase inhibitor","labels":["DRUG"]},"id":"jZUkOQ2ZER","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:10:00.287604Z","updated_at":"2025-12-26T09:10:00.287604Z","draft_created_at":"2025-12-26T09:08:02.074790Z","lead_time":175.678,"prediction":{},"result_count":5,"unique_id":"e1bb4dea-f531-4d6f-bf56-731424f69776","import_id":null,"last_action":null,"bulk_created":false,"task":70,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The purpose of this study is to evaluate the efficacy and quality of life in women with advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the breast), HR+ \/ HER2-, who are treated with an aromatase inhibitor or fulvestrant as baseline therapy in combination with palbociclib (Ibrance)"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:10:00.345604Z","allow_skip":true,"inner_id":70,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":71,"annotations":[{"id":71,"completed_by":1,"result":[{"value":{"start":77,"end":85,"text":"phase II","labels":["STUDY_PHASE"]},"id":"8nTEJGIMhl","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":116,"end":138,"text":"advanced breast cancer","labels":["CONDITION"]},"id":"21YMa3SIyV","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":106,"end":115,"text":"HR+\/HER2-","labels":["PATIENT_CRITERIA"]},"id":"30X4iD7N-k","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":149,"end":161,"text":"palbociclib ","labels":["DRUG"]},"id":"Oi3sSfteD4","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":202,"end":213,"text":"fulvestrant","labels":["DRUG"]},"id":"X8q8iwvv-4","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":179,"end":198,"text":"aromatase inhibitor","labels":["DRUG"]},"id":"qOrT9gX5sy","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:11:10.505793Z","updated_at":"2025-12-26T09:11:10.505793Z","draft_created_at":"2025-12-26T09:10:36.077709Z","lead_time":66.912,"prediction":{},"result_count":6,"unique_id":"6424a5fa-86ab-4dd6-97dd-8834a94b03e7","import_id":null,"last_action":null,"bulk_created":false,"task":71,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This is a prospective, open-label, multi-center, single arm, non-comparative phase II study in women with HR+\/HER2- advanced breast cancer receiving palbociclib in addition to an aromatase inhibitor or fulvestrant."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:11:10.558797Z","allow_skip":true,"inner_id":71,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":72,"annotations":[{"id":72,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:13:05.839152Z","updated_at":"2025-12-26T09:13:05.840153Z","draft_created_at":null,"lead_time":113.05,"prediction":{},"result_count":0,"unique_id":"bed9492e-c184-4484-b3b0-39379d056138","import_id":null,"last_action":null,"bulk_created":false,"task":72,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The study will take place in Germany (85 study centers)."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:13:05.868153Z","allow_skip":true,"inner_id":72,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":73,"annotations":[{"id":73,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:17:18.188677Z","updated_at":"2025-12-26T09:17:18.188677Z","draft_created_at":null,"lead_time":251.016,"prediction":{},"result_count":0,"unique_id":"4fa309bb-78af-45f5-b9d3-9212bf47e42e","import_id":null,"last_action":null,"bulk_created":false,"task":73,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"In total, 360 patients will be enrolled in this study."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:17:18.227675Z","allow_skip":true,"inner_id":73,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":74,"annotations":[{"id":74,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:20:03.569017Z","updated_at":"2025-12-26T09:20:03.569017Z","draft_created_at":null,"lead_time":164.08,"prediction":{},"result_count":0,"unique_id":"78e28ecc-520e-4ab7-912b-d3ce637a46f8","import_id":null,"last_action":null,"bulk_created":false,"task":74,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"6 treatment groups are planned."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:20:03.614017Z","allow_skip":true,"inner_id":74,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":75,"annotations":[{"id":75,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:20:21.338553Z","updated_at":"2025-12-26T09:20:21.338553Z","draft_created_at":null,"lead_time":16.336,"prediction":{},"result_count":0,"unique_id":"14ca88e3-e7d3-4259-9bfd-459999d35060","import_id":null,"last_action":null,"bulk_created":false,"task":75,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The study seeks to recruit 60 (58-62) patients per recruitment group."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:20:21.374556Z","allow_skip":true,"inner_id":75,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":76,"annotations":[{"id":76,"completed_by":1,"result":[{"value":{"start":0,"end":263,"text":"Inclusion: 1. Personally signed written informed consent prior to beginning protocol specific procedures, including expected cooperation of the patient for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements","labels":["PATIENT_CRITERIA"]},"id":"Af0Pxrp2Uy","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:20:46.868151Z","updated_at":"2025-12-26T09:20:46.868151Z","draft_created_at":null,"lead_time":23.488,"prediction":{},"result_count":1,"unique_id":"383cd6ee-afdb-4ecc-870c-574909502e7d","import_id":null,"last_action":null,"bulk_created":false,"task":76,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: 1. Personally signed written informed consent prior to beginning protocol specific procedures, including expected cooperation of the patient for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:20:46.904148Z","allow_skip":true,"inner_id":76,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":77,"annotations":[{"id":77,"completed_by":1,"result":[{"value":{"start":0,"end":137,"text":"Inclusion: 2. Women with proven diagnosis of advanced, defined as locally advanced inoperable or metastatic, adenocarcinoma of the breast","labels":["PATIENT_CRITERIA"]},"id":"4dfXKx5ln6","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":74,"end":137,"text":"advanced inoperable or metastatic, adenocarcinoma of the breast","labels":["CONDITION"]},"id":"dXM9ons13w","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:21:25.948266Z","updated_at":"2025-12-26T09:21:25.948266Z","draft_created_at":"2025-12-26T09:21:02.080693Z","lead_time":37.611,"prediction":{},"result_count":2,"unique_id":"6f743963-4993-48a1-b018-373d2c5c06b7","import_id":null,"last_action":null,"bulk_created":false,"task":77,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Inclusion: 2. Women with proven diagnosis of advanced, defined as locally advanced inoperable or metastatic, adenocarcinoma of the breast"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:21:25.988265Z","allow_skip":true,"inner_id":77,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":78,"annotations":[{"id":78,"completed_by":1,"result":[{"value":{"start":3,"end":132,"text":"Hormone-receptor-positive (HR+) disease, defined as estrogen-receptor-positive (ER+) and\/or progesterone-receptor-positive (PgR+)","labels":["PATIENT_CRITERIA"]},"id":"eNRqO9YMy2","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":30,"end":33,"text":"HR+","labels":["BIOMARKER"]},"id":"VeAQUxgZ3-","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":83,"end":86,"text":"ER+","labels":["BIOMARKER"]},"id":"KOKuFa7NWr","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":127,"end":131,"text":"PgR+","labels":["BIOMARKER"]},"id":"sWwg3AUSKb","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:22:26.653420Z","updated_at":"2025-12-26T09:22:26.653420Z","draft_created_at":"2025-12-26T09:22:04.233363Z","lead_time":55.048,"prediction":{},"result_count":4,"unique_id":"aaf1e799-be79-4f02-833b-26bcdf00d072","import_id":null,"last_action":null,"bulk_created":false,"task":78,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"3. Hormone-receptor-positive (HR+) disease, defined as estrogen-receptor-positive (ER+) and\/or progesterone-receptor-positive (PgR+)"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:22:26.705421Z","allow_skip":true,"inner_id":78,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":79,"annotations":[{"id":79,"completed_by":1,"result":[{"value":{"start":54,"end":59,"text":"HER2-","labels":["BIOMARKER"]},"id":"FjJ5FFn7uJ","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":3,"end":111,"text":"Human epidermal growth factor receptor 2-negative (HER2-) disease (HER2 neg\/+ or HER2++ with CISH\/FISH neg.)","labels":["PATIENT_CRITERIA"]},"id":"Xl9TReKojC","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":70,"end":80,"text":"HER2 neg\/+","labels":["BIOMARKER"]},"id":"wY2CG68mlL","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":84,"end":90,"text":"HER2++","labels":["BIOMARKER"]},"id":"4LM6X9JsBL","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:24:15.903691Z","updated_at":"2025-12-26T09:24:15.903691Z","draft_created_at":"2025-12-26T09:23:03.467546Z","lead_time":106.595,"prediction":{},"result_count":4,"unique_id":"485bbf45-3e29-49e0-9430-cb4fa5c366f2","import_id":null,"last_action":null,"bulk_created":false,"task":79,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"4. Human epidermal growth factor receptor 2-negative (HER2-) disease (HER2 neg\/+ or HER2++ with CISH\/FISH neg.)"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:24:15.957692Z","allow_skip":true,"inner_id":79,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":80,"annotations":[{"id":80,"completed_by":1,"result":[{"value":{"start":18,"end":45,"text":"Clinical Benefit Rate (CBR)","labels":["ENDPOINT"]},"id":"Kcf2tAmypa","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:24:42.248786Z","updated_at":"2025-12-26T09:24:42.248786Z","draft_created_at":null,"lead_time":23.822,"prediction":{},"result_count":1,"unique_id":"f7e3155b-6399-4090-9f81-7533f04bb77f","import_id":null,"last_action":null,"bulk_created":false,"task":80,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Clinical Benefit Rate (CBR) [Time Frame: 24 weeks after first administration of Palbociclib in combination with AI \/ fulvestrant]"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:24:42.297790Z","allow_skip":true,"inner_id":80,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":81,"annotations":[{"id":81,"completed_by":1,"result":[{"value":{"start":6,"end":18,"text":"Palbociclib ","labels":["DRUG"]},"id":"iHsRqmEQ18","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":87,"end":138,"text":"125mg daily, 21 days, 7 days off, cycles of 28 days","labels":["DOSAGE"]},"id":"5bfH_tPXnT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":141,"end":169,"text":"Dose reductions: 100mg, 75mg","labels":["DOSAGE"]},"id":"BaFlspXz3H","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:25:59.863959Z","updated_at":"2025-12-26T09:25:59.863959Z","draft_created_at":"2025-12-26T09:25:42.659930Z","lead_time":72.381,"prediction":{},"result_count":3,"unique_id":"3a1495a1-f41a-4a39-88dc-16bf2813cf9e","import_id":null,"last_action":null,"bulk_created":false,"task":81,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"DRUG: Palbociclib - Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.\n\nDose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:25:59.902958Z","allow_skip":true,"inner_id":81,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":82,"annotations":[{"id":82,"completed_by":1,"result":[{"value":{"start":80,"end":94,"text":"dexamethasone ","labels":["DRUG"]},"id":"V-ubctT2zp","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":113,"end":123,"text":"paclitaxel","labels":["DRUG"]},"id":"TLSbA4ouB0","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":228,"end":291,"text":"receiving first cycle of combination paclitaxel and carboplatin","labels":["PATIENT_CRITERIA"]},"id":"vvaCkaD75Y","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":280,"end":291,"text":"carboplatin","labels":["DRUG"]},"id":"wDc2162PbT","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":165,"end":218,"text":"primary ovarian, fallopian tube and peritoneal cancer","labels":["CONDITION"]},"id":"pQnqj19zon","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:28:46.418359Z","updated_at":"2025-12-26T09:28:46.418359Z","draft_created_at":"2025-12-26T09:26:40.857055Z","lead_time":164.971,"prediction":{},"result_count":5,"unique_id":"a3f2bef8-0f7d-482b-b349-7c0c85ed3d5c","import_id":null,"last_action":null,"bulk_created":false,"task":82,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Comparison of the efficacy and side effects of intravenous and oral regimens of dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reactions in primary ovarian, fallopian tube and peritoneal cancer patients receiving first cycle of combination paclitaxel and carboplatin."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:28:46.455359Z","allow_skip":true,"inner_id":82,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":83,"annotations":[{"id":83,"completed_by":1,"result":[{"value":{"start":85,"end":96,"text":"paclitaxel ","labels":["DRUG"]},"id":"SakkpqOgH6","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":97,"end":116,"text":"175 mg\/m2 over 3 hr","labels":["DOSAGE"]},"id":"V2C-2wNz01","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":135,"end":147,"text":"carboplatin ","labels":["DRUG"]},"id":"Dj9j5Ac4R1","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":170,"end":194,"text":"[AUC\\] 5.0-7.5 mg\/ml∙min","labels":["DOSAGE"]},"id":"3kvx89ZBHk","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":46,"end":60,"text":"ovarian cancer","labels":["CONDITION"]},"id":"tSHbUMuHYW","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:30:39.982672Z","updated_at":"2025-12-26T09:30:39.983671Z","draft_created_at":"2025-12-26T09:30:10.757557Z","lead_time":111.644,"prediction":{},"result_count":5,"unique_id":"6e08edeb-118e-4780-a2f6-a9d65a5a1bab","import_id":null,"last_action":null,"bulk_created":false,"task":83,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The consensus statements on the management of ovarian cancer recommended intravenous paclitaxel (175 mg\/m2 over 3 hr) plus intravenous carboplatin (area under the curve \\[AUC\\] 5.0-7.5 mg\/ml∙min) given every 3 weeks for six cycles for first-line chemotherapy."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:30:40.029671Z","allow_skip":true,"inner_id":83,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":84,"annotations":[{"id":84,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:31:22.740812Z","updated_at":"2025-12-26T09:31:22.740812Z","draft_created_at":null,"lead_time":9.998,"prediction":{},"result_count":0,"unique_id":"ae4aa85b-df78-4001-8c7b-be889bacdc25","import_id":null,"last_action":null,"bulk_created":false,"task":84,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"A major limitation of paclitaxel was its poor water solubility, which led to the use of polyoxyethylated castor oil vehicle or Cremophor® EL as diluents resulted a hypersensitivity reactions (HSRs)."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:31:22.769811Z","allow_skip":true,"inner_id":84,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":85,"annotations":[{"id":85,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:31:26.542810Z","updated_at":"2025-12-26T09:31:26.542810Z","draft_created_at":null,"lead_time":2.61,"prediction":{},"result_count":0,"unique_id":"735fb0b1-741b-42b6-bf03-2fdbc1268606","import_id":null,"last_action":null,"bulk_created":false,"task":85,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Initial P-HSRs generally occur within 10 minutes of the start of paclitaxel infusion and most occur with the first or second infusion."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:31:26.572812Z","allow_skip":true,"inner_id":85,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":86,"annotations":[{"id":86,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:31:40.385841Z","updated_at":"2025-12-26T09:31:40.385841Z","draft_created_at":null,"lead_time":12.28,"prediction":{},"result_count":0,"unique_id":"288539b0-3099-48e5-903c-09ba8010efee","import_id":null,"last_action":null,"bulk_created":false,"task":86,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Majority of patients manifest as minor symptoms characterized by flushing and rashes but sometime life-threatening characterized by generalized urticaria, angioedema, bronchospasm and hypertension or until fatal may occur."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:31:40.423841Z","allow_skip":true,"inner_id":86,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":87,"annotations":[{"id":87,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:31:59.378902Z","updated_at":"2025-12-26T09:31:59.378902Z","draft_created_at":null,"lead_time":17.933,"prediction":{},"result_count":0,"unique_id":"94c967c0-b306-498f-b11b-424f6c5f3f2c","import_id":null,"last_action":null,"bulk_created":false,"task":87,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The reaction is likely due to the release of histamine and other vasoactive substances in response to Cremophor EL."},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:31:59.417902Z","allow_skip":true,"inner_id":87,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":88,"annotations":[{"id":88,"completed_by":1,"result":[{"value":{"start":0,"end":92,"text":"Patient pathologically diagnosed with primary ovarian or fallopian tube or peritoneal cancer","labels":["PATIENT_CRITERIA"]},"id":"W4D5cU7g7X","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":46,"end":92,"text":"ovarian or fallopian tube or peritoneal cancer","labels":["CONDITION"]},"id":"sOvNySGN6B","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:32:31.552485Z","updated_at":"2025-12-26T09:32:31.552485Z","draft_created_at":"2025-12-26T09:32:17.010952Z","lead_time":31.132,"prediction":{},"result_count":2,"unique_id":"97751134-8f2a-44d4-9af5-a6a4ea6d5dfa","import_id":null,"last_action":null,"bulk_created":false,"task":88,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Patient pathologically diagnosed with primary ovarian or fallopian tube or peritoneal cancer"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:32:31.590483Z","allow_skip":true,"inner_id":88,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":89,"annotations":[{"id":89,"completed_by":1,"result":[{"value":{"start":0,"end":137,"text":"Patient starting a first cycle of combination paclitaxel and carboplatin at Rajavithi Hospital between February 1, 2015 and July 31, 2015","labels":["PATIENT_CRITERIA"]},"id":"X6N-aOkTwl","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":46,"end":57,"text":"paclitaxel ","labels":["DRUG"]},"id":"WafzUml4oa","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":61,"end":73,"text":"carboplatin ","labels":["DRUG"]},"id":"H4S-Ia6x--","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:33:04.980095Z","updated_at":"2025-12-26T09:33:04.980095Z","draft_created_at":"2025-12-26T09:33:03.286094Z","lead_time":26.873,"prediction":{},"result_count":3,"unique_id":"e4add76e-5f5e-4513-a14d-7e137a08405d","import_id":null,"last_action":null,"bulk_created":false,"task":89,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Patient starting a first cycle of combination paclitaxel and carboplatin at Rajavithi Hospital between February 1, 2015 and July 31, 2015"},"meta":{},"created_at":"2025-12-25T17:15:25.263786Z","updated_at":"2025-12-26T09:33:05.018095Z","allow_skip":true,"inner_id":89,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":90,"annotations":[{"id":90,"completed_by":1,"result":[{"value":{"start":0,"end":40,"text":"Patient with ECOG performance status 0-2","labels":["PATIENT_CRITERIA"]},"id":"IuyOLoGovy","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:33:31.431665Z","updated_at":"2025-12-26T09:33:31.431665Z","draft_created_at":"2025-12-26T09:33:15.353113Z","lead_time":24.079,"prediction":{},"result_count":1,"unique_id":"f7980ecb-7f03-4d0e-ba28-32a6d70b9070","import_id":null,"last_action":null,"bulk_created":false,"task":90,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Patient with ECOG performance status 0-2"},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:33:31.462665Z","allow_skip":true,"inner_id":90,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":91,"annotations":[{"id":91,"completed_by":1,"result":[{"value":{"start":0,"end":244,"text":"Patient with the following laboratory values obtained: Hemoglobin \\> 10 g\/dL, Absolute neutrophil count \\> 1500 \/mm3, Platelet count \\> 100,000\/mm3, Serum creatinine \\> 2.0 mg\/dL, Bilirubin \\> 1.5 x ULN, alkaline phosphatase and SGOT \\> 3 x ULN","labels":["PATIENT_CRITERIA"]},"id":"cBaBeBNeW7","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:33:54.592247Z","updated_at":"2025-12-26T09:33:54.592247Z","draft_created_at":null,"lead_time":21.977,"prediction":{},"result_count":1,"unique_id":"a79ef776-9a97-460b-8be5-751cdc527ed8","import_id":null,"last_action":null,"bulk_created":false,"task":91,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Patient with the following laboratory values obtained: Hemoglobin \\> 10 g\/dL, Absolute neutrophil count \\> 1500 \/mm3, Platelet count \\> 100,000\/mm3, Serum creatinine \\> 2.0 mg\/dL, Bilirubin \\> 1.5 x ULN, alkaline phosphatase and SGOT \\> 3 x ULN"},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:33:54.623250Z","allow_skip":true,"inner_id":91,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":92,"annotations":[{"id":92,"completed_by":1,"result":[{"value":{"start":18,"end":105,"text":"Incidence of Paclitaxel-Associated Hypersensitivity Reaction (P-HSRs) and severe P-HSRs","labels":["ENDPOINT"]},"id":"k69LXEzbsF","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:35:55.052517Z","updated_at":"2025-12-26T09:35:55.052517Z","draft_created_at":null,"lead_time":118.866,"prediction":{},"result_count":1,"unique_id":"dbec9d15-f9cb-4935-905b-62f0bbc1f635","import_id":null,"last_action":null,"bulk_created":false,"task":92,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"Primary endpoint: Incidence of Paclitaxel-Associated Hypersensitivity Reaction (P-HSRs) and severe P-HSRs (Safety endpoint) [Time Frame: 3 Hours after starting paclitaxel infusion]"},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:35:55.086518Z","allow_skip":true,"inner_id":92,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":93,"annotations":[{"id":93,"completed_by":1,"result":[{"value":{"start":18,"end":32,"text":"Dexamethasone ","labels":["DRUG"]},"id":"69NefMJF-J","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":52,"end":119,"text":"5 tablets given orally at 12 and 6 hours before paclitaxel infusion","labels":["DOSAGE"]},"id":"h-hCpZHTHj","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":138,"end":213,"text":"20 mg (5mg\/ml) given intravenously at 30 minutes before paclitaxel infusion","labels":["DOSAGE"]},"id":"WH0pRBJrmF","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:36:55.395715Z","updated_at":"2025-12-26T09:36:55.395715Z","draft_created_at":"2025-12-26T09:36:35.435660Z","lead_time":58.291,"prediction":{},"result_count":3,"unique_id":"f2287ad2-f37c-455a-8de1-552967b59650","import_id":null,"last_action":null,"bulk_created":false,"task":93,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"DRUG: Intravenous Dexamethasone - Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg\/ml) given intravenously at 30 minutes before paclitaxel infusion"},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:36:55.429714Z","allow_skip":true,"inner_id":93,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":94,"annotations":[{"id":94,"completed_by":1,"result":[{"value":{"start":5,"end":12,"text":"phase I","labels":["STUDY_PHASE"]},"id":"fZ5o3xOmIj","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":68,"end":113,"text":"TAG72-chimeric antigen receptor (CAR) T cells","labels":["DRUG"]},"id":"HDUU-VwHI5","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":140,"end":165,"text":"epithelial ovarian cancer","labels":["CONDITION"]},"id":"1Pc8lms62L","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":220,"end":238,"text":"platinum resistant","labels":["PATIENT_CRITERIA"]},"id":"HUqIS9ob5U","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:38:21.824427Z","updated_at":"2025-12-26T09:38:21.824427Z","draft_created_at":"2025-12-26T09:37:45.207839Z","lead_time":85.015,"prediction":{},"result_count":4,"unique_id":"8ca5acea-0e4c-42fd-b1b1-755a80c87946","import_id":null,"last_action":null,"bulk_created":false,"task":94,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant)."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:38:21.877424Z","allow_skip":true,"inner_id":94,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":95,"annotations":[{"id":95,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:38:41.933487Z","updated_at":"2025-12-26T09:38:41.933487Z","draft_created_at":null,"lead_time":18.613,"prediction":{},"result_count":0,"unique_id":"1d8172aa-99cb-4ae3-90dc-785fac149a32","import_id":null,"last_action":null,"bulk_created":false,"task":95,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"T cells are infection fighting blood cells that can kill tumor cells."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:38:41.960486Z","allow_skip":true,"inner_id":95,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":96,"annotations":[{"id":96,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:38:58.342038Z","updated_at":"2025-12-26T09:38:58.342038Z","draft_created_at":null,"lead_time":15.266,"prediction":{},"result_count":0,"unique_id":"d6ae5024-d5af-438d-a527-f125c92701d1","import_id":null,"last_action":null,"bulk_created":false,"task":96,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:38:58.374039Z","allow_skip":true,"inner_id":96,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":97,"annotations":[{"id":97,"completed_by":1,"result":[],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:39:17.252090Z","updated_at":"2025-12-26T09:39:17.252090Z","draft_created_at":null,"lead_time":17.339,"prediction":{},"result_count":0,"unique_id":"f817a3fd-85a7-4621-9174-18ac20a67fc7","import_id":null,"last_action":null,"bulk_created":false,"task":97,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:39:17.287092Z","allow_skip":true,"inner_id":97,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":98,"annotations":[{"id":98,"completed_by":1,"result":[{"value":{"start":43,"end":60,"text":"TAG72-CAR T cells","labels":["DRUG"]},"id":"S4hgId-fC5","from_name":"label","to_name":"text","type":"labels","origin":"manual"},{"value":{"start":82,"end":123,"text":"recurrent epithelial ovarian cancer (EOC)","labels":["CONDITION"]},"id":"dbgrUWXxc_","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:39:49.420164Z","updated_at":"2025-12-26T09:39:49.420164Z","draft_created_at":"2025-12-26T09:39:44.976162Z","lead_time":30.781,"prediction":{},"result_count":2,"unique_id":"d0329f33-f07f-48cc-97c3-82c69c157c36","import_id":null,"last_action":null,"bulk_created":false,"task":98,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"To evaluate the safety and tolerability of TAG72-CAR T cells in participants with recurrent epithelial ovarian cancer (EOC)."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:39:49.453166Z","allow_skip":true,"inner_id":98,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":99,"annotations":[{"id":99,"completed_by":1,"result":[{"value":{"start":20,"end":48,"text":"maximum tolerated dose (MTD)","labels":["ENDPOINT"]},"id":"2DssHd2GbO","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:40:17.961235Z","updated_at":"2025-12-26T09:40:17.961235Z","draft_created_at":null,"lead_time":25.309,"prediction":{},"result_count":1,"unique_id":"19914bdd-4222-481b-bd3e-c73418661243","import_id":null,"last_action":null,"bulk_created":false,"task":99,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"II To determine the maximum tolerated dose (MTD)."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:40:17.995238Z","allow_skip":true,"inner_id":99,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]},{"id":100,"annotations":[{"id":100,"completed_by":1,"result":[{"value":{"start":16,"end":47,"text":"recommended phase 2 dose (RP2D)","labels":["ENDPOINT"]},"id":"vn5HnROXvI","from_name":"label","to_name":"text","type":"labels","origin":"manual"}],"was_cancelled":false,"ground_truth":false,"created_at":"2025-12-26T09:40:40.530295Z","updated_at":"2025-12-26T09:40:40.530295Z","draft_created_at":null,"lead_time":20.325,"prediction":{},"result_count":1,"unique_id":"094dbca9-8417-4b17-bdd2-93d3ffa45006","import_id":null,"last_action":null,"bulk_created":false,"task":100,"project":1,"updated_by":1,"parent_prediction":null,"parent_annotation":null,"last_created_by":null}],"file_upload":"72fa086d-real_clinical_trials.json","drafts":[],"predictions":[],"data":{"text":"To identify the recommended phase 2 dose (RP2D)."},"meta":{},"created_at":"2025-12-25T17:15:25.264785Z","updated_at":"2025-12-26T09:40:40.571295Z","allow_skip":true,"inner_id":100,"total_annotations":1,"cancelled_annotations":0,"total_predictions":0,"comment_count":0,"unresolved_comment_count":0,"last_comment_updated_at":null,"project":1,"updated_by":1,"comment_authors":[]}]